1.

Identification and validation of novel therapeutic or diagnostic targets, focusing on transformation mechanisms using a range of hematopathy models, including those mimicking pre-leukemia stages.

a. Identification and preclinical confirmation

b. Animal models and in vivo validation

c. Drug design

2.

Screening and treatment efficacy validation 

a. Screening and/or repositioning of existing drugs or their combinations

b. Pharmacodynamic and efficacy biomarkers

c. Mechanisms of resistance, effect on hemopathy-initiating cells